{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"48.5","value":"23.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"}],"units":"Participants"}],"description":"Median Cmin (measured as milligrams per liter \\[mg/L\\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.","id":"OG000","title":"Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)"}],"paramType":"MEDIAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106","title":"Trastuzumab Minimum Serum Concentration (Cmin)","type":"SECONDARY","unitOfMeasure":"mg/L"}